Plain-English translation of NCT06828588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of imaging scan called that helps doctors see HER2 protein levels in your cancer cells. The scan is designed to track how well your HER2-targeted therapy is working throughout your treatment. Researchers believe this new imaging tool could help doctors better understand whether your current treatment plan is effective.
Current imaging methods sometimes can't tell doctors whether HER2-targeted therapy is truly working at the cellular level. This study hopes to show that the new imaging scan can provide clearer information about how your cancer is responding to treatment, which could help your doctors make better decisions about your care.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the study medication followed by a PET/CT imaging scan on the same day. You would return for a follow-up visit 2–7 days after the injection to check for any side effects. Depending on your treatment plan, you may have a second imaging scan either when your HER2-targeted therapy ends or at 12 months after joining the study, whichever comes first. You'll continue your regular cancer care as planned by your treatment team.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States